Moreover, DNA damage proteins and cancer cells have specific properties, including cancer-specific DDR defects and lack of G1 checkpoint control, that may highlight particular vulnerabilities of the cancer [122], supporting PARP, ATR, ATM, CHK1/2, and WEE1 as therapeutic targets. Here, PROS1 is linked to cancer.